Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trigeminovascular activation during preventive treatment for migraine and cluster headache
NL-OMON50257Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of anti-CGRP monoclonal antibodies, candesartan and capsaicin in migraine and Cluster Headache (CH) (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Dermal blood flow response to capsaicin application and Dermal blood flow response to electrical stimulation. Started Dec 2018; status: recruiting.
02
Drugs
anti-CGRP monoclonal antibodiescandesartancapsaicin
03
Conditions
migraineCluster Headache (CH)
Beyond the preview
Go deeper on NL-OMON50257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50257.